Literature DB >> 22975562

Opsoclonus-myoclonus syndrome following influenza a infection.

Akihiko Morita1, Masaki Ishihara, Satoshi Kamei, Hiroshi Ishikawa.   

Abstract

A 60-year-old woman developed opsoclonus-myoclonus syndrome (OMS) a week after being diagnosed with influenza A infection by a rapid antigen test. She had no loss of consciousness. Opsoclonus, myoclonus, and truncal ataxia were noted. Two weeks after treatment with intravenous immunoglobulin and corticosteroids, her opsoclonus, myoclonus, and truncal ataxia disappeared. No malignant tumors were detected during the 3-year follow-up period. There has been no previous report of postinfectious OMS following confirmed influenza A infection. OMS without a loss of consciousness has been reported to be statistically less common in cases of non-paraneoplastic OMS. This finding was consistent with the present patient's clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975562     DOI: 10.2169/internalmedicine.51.7627

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  West nile virus encephalitis induced opsoclonus-myoclonus syndrome.

Authors:  Chad J Cooper; Sarmad Said
Journal:  Neurol Int       Date:  2014-04-22

Review 2.  The diagnostic value of saccades in movement disorder patients: a practical guide and review.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Janet C Rucker; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2015-10-15

3.  Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature.

Authors:  Angelina Maria Martins Lino; Raphael Ribeiro Spera; Fernando Peixoto Ferraz de Campos; Christian Henrique de Andrade Freitas; Márcio Ricardo Taveira Garcia; Leonardo da Costa Lopes; Aleksander Snioka Prokopowitsch
Journal:  Autops Case Rep       Date:  2014-03-31

4.  Movement disorders of probable infectious origin.

Authors:  Ketan Jhunjhunwala; M Netravathi; Pramod Kumar Pal
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.